Key result
Clozapine exposure in 258,961 patients was associated with low event rates of myocarditis (0.007; 95% CI 0.003-0.016) and cardiomyopathy (0.006; 95% CI 0.002-0.023).
Why the study?
Clozapine causes serious cardiac adverse drug reactions, but reported rates of myocarditis and cardiomyopathy vary across the literature.
Meta-Analysis (n=258,961)
Yes
The risks of myocarditis and cardiomyopathy associated with clozapine are low (event rates <1%) and should not present a barrier to its use in treatment-refractory schizophrenia, though monitoring in the first 4 weeks is warranted.
Authors
No takes yet. Share an insight, caveat, or question.
Supports cardiac monitoring with clozapine; extends pooled incidence estimates from observational data.
Siskind et al. (2020) conducted a meta-analysis in Treatment refractory schizophrenia (n=258,961). Clozapine was evaluated on Myocarditis event rate (95% CI 0.003, 0.016). Clozapine exposure in 258,961 patients was associated with low event rates of myocarditis (0.007; 95% CI 0.003-0.016) and cardiomyopathy (0.006; 95% CI 0.002-0.023).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: